Ascentage Granted China Priority Review of NDA for BCR-ABL Inhibitor

Suzhou Ascentage Pharma reported its New Drug Application for Olverembatinib (HQP1351) will be reviewed under priority status in China . According to Ascentage, Olverembatinib is a third-gen BCR-ABL inhibitor because it is able to overcome resistance caused by tyrosine kinase mutations, especially T315I-caused resistance. Olverembatinib, which was tested in patients with T315I-mutant chronic CML and accelerated CML, is Ascentage's first China NDA submission. More details.... Stock Symbol: (HK: 6855) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.